Research from Atrium Research, Atrium Research Corporation

Atrium Research

Atrium Research provides institutional quality issuer paid research on public equities in North America. Our investment philosophy takes a 3-5 year view on equities currently being overlooked by the market. Our research process emphasizes understanding the key performance metrics for each specific company, trustworthy management teams, unit economics, and an in-depth valuation analysis.

Our research product includes in-depth initiation reports, research notes, thematic research pieces, and company fact sheets.

Research from Atrium Research

Atrium Research Corporation

Atrium Research provides institutional quality issuer paid research on public equities in North America. Our investment philosophy takes a 3-5 year view on equities currently being overlooked by the market. Our research process emphasizes understanding the key performance metrics for each specific company, trustworthy management teams, unit economics, and an in-depth valuation analysis. 

Our research product includes in-depth initiation reports, research notes, thematic research pieces, and company fact sheets.

Equity Bottom-Up

<ul>
<li>CTEK reported a softer Q1, with revenue of $3.5M (-5% YoY) vs. our $3.8M estimate and Adjusted EBITDA was $1.0M (28% margin) compared to our estimate of $1.2M.</li>
<li>Management utilized the quarter to prepare for the step-change in revenue ahead as it executes on its large international order starting in Q2.</li>
<li>We recently interviewed CEO Riley Taggart, watch it here.</li>
</ul>


CTEK reported a softer Q1, with revenue of $3.5M (-5% YoY) vs. our $3.8M estimate and Adjusted EBITDA was $1.0M (28% margin) compared to our estimate of $1.2M.
Management utilized the quarter to prepare for the step-change in revenue ahead as it executes on its large international order starting in Q2.
We recently interviewed CEO Riley Taggart, watch it here.


CTEK: Uneventful Q1; Expecting Step-Change in Q2 & Q3

Cleantek Industries

CTEK: Uneventful Q1; Expecting Step-Change in Q2 & Q3